Quantum BioPharma Forges Strategic Partnership with Allucent for Multiple Sclerosis Clinical Trial
Quantum BioPharma Ltd., a biopharmaceutical company trading on NASDAQ, CSE, and FRA under the symbol QNTM, has announced a significant advancement in its clinical development pipeline. The company has entered into a binding Letter of Intent with Allucent, a global contract research organization specializing in central nervous system clinical trials, to support the upcoming Phase 2 clinical trial of Lucid-21-302, known as Lucid-MS, for the treatment of multiple sclerosis.
A Milestone in Neurodegenerative Disease Treatment
This strategic partnership represents a crucial milestone in Quantum BioPharma's commitment to developing innovative solutions for patients suffering from debilitating mobility conditions associated with multiple sclerosis. The collaboration with Allucent, which brings extensive experience in supporting complex clinical trials, underscores the company's dedication to advancing a potentially groundbreaking therapeutic approach that differs significantly from existing market solutions.
The planned Phase 2 trial is scheduled to commence in the second quarter of 2026, pending regulatory approvals and finalization of clinical trial design and operational arrangements. The study will comprehensively evaluate the efficacy, safety, and tolerability of Lucid-MS in people diagnosed with multiple sclerosis, with particular attention to how the treatment's mechanism relates to established clinical and radiographic markers of disease activity.
Comprehensive Clinical Trial Services
Under the terms of the binding Letter of Intent, Allucent will provide a comprehensive suite of clinical trial services designed to ensure efficient execution and maintain rigorous data integrity throughout the study. These services include:
- Study Start-Up: Managing regulatory submissions and ethics approvals to accelerate trial initiation
- Site Selection & Management: Coordinating a global site network to optimize patient access
- Patient Recruitment: Developing and executing enrollment strategies for efficient trial completion
- Data Management: Ensuring collection, analysis, and reporting maintain rigorous clinical data integrity
- Regulatory Support: Facilitating agency interactions and compliance for a streamlined development pathway
The parties are expected to finalize a more comprehensive and definitive services agreement in the coming weeks, solidifying this strategic partnership that could significantly impact multiple sclerosis treatment worldwide.
First-in-Class Therapeutic Innovation
Lucid-MS represents a first-in-class, new chemical entity therapeutic innovation designed to provide neuroprotection through the inhibition of demyelination—a key driver of disease progression in multiple sclerosis. This innovative mechanism offers a differentiated therapeutic approach in the global MS market, where current treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration directly.
"Lucid-MS is a First-in-Class, New Chemical Entity, Therapeutic Innovation designed to provide neuroprotection through the inhibition of demyelination, a key driver of disease progression in MS," explained Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum BioPharma. "This innovative mechanism represents a differentiated therapeutic approach in the global MS market where an estimated 2.8 million people suffer and where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration."
The global multiple sclerosis therapeutic market continues to expand as researchers seek more effective treatments for this chronic autoimmune disease that affects the central nervous system. Quantum BioPharma's partnership with Allucent positions the company to potentially address a significant unmet medical need for the millions of patients worldwide living with multiple sclerosis.
